what are glp-1 agonists Resmetirom and for MASH: complementary rather than exclusive How GLP-1 Receptor Agonists Evolved

(2021), has driven significant pharmacological development

Lancet Neurol 14(3):329340 Biessels GJ, Verhagen C, Janssen J et al (2019) Effect of linagliptin on cognitive performance in patients with type 2 diabetes and cardiorenal comorbidities: the CARMELINA randomized trial

Based on gathered evidence, DPP-4 may reduce the putative positive impact of adiponectin on bone mass [85]

While the mechanisms for GLP-1RAs primary insulinotropic effects are clear, such clarity is not apparent for their other effects

However, there are many similarities between the two

Among patients with pre-transplant diabetes, outcomes aligned with the main findings